43%) than males ( p < 0.05). Genotype (Gt) 1 (70% and 64%) and 2 (20% and 14%) were more prevalent in females compared to Gt 3 (15% vs 7%) and 4 (10% vs 3%) which were more prevalent in males. F0-F1 fibrosis stage was significantly more prevalent in females (59%) vs males (33%). Sixty-six% of females and 44% of males younger than 50 years had F0-F1 fibrosis. F4/cirrhosis was significantly higher in males (39%) vs females (28%)(p < 0.05). In males F4/cirrhosis was present in 30% and 43% of those younger and older than 50 years of age respectively and in females in 11% vs. 30% respectively reaching the same distribution after 60 years (Figure 1). In females ALTs were significantly higher (p < 0.001) in each fibrosis stage whereas the prevalence of HIVand HBsAg coinfections were significantly lower (4% vs 8% p < 0.05 and 1% vs 2% respectively). 46% of females were previously treated with IFN-based therapy compared to 63% of males. Of those treated 40% of females and 27% of males (p < 0.05) had F0-F1 fibrosis whereas 34% of female vs. 44% of males had F4 /cirrhosis. Hypertension (28% vs20%), osteoarticular diseases (10.4% vs 3.1%) and tumours (7.1 vs 3.6%) were significantly higher in females. Male gender, increased BMI, previous alcohol use, genotype 3 and diabetes were independently associated with cirrhosis by logistic regression analysis. Conclusions: In this large cohort of Italian patients, female gender was not indipendentlyassociated to cirrhosis. Females younger than 50 years had significantly lower fibrosis compared to men, however risk of cirrhosis in females increased significantly in women older than 60 years. DAAtherapies should therefore be made available to females before occurence of menopause considering the high rate of cirrhosis in women older than 60 years of age. FRI-181 HCV–RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY L. Kondili 1 , L.E. Weimer 1 , A. Mallano 1 , L. Fucili 1 , M. Massella 1 , M. Vinci 2 , G. Borgia 3 , M. Brunetto 4 , L. Surace 4 , G.B. Gaeta 5 , L. Chemello 6 , P. Andreone 7 , G. Raimondo 8 , R. Filomia 8 , M. Persico 9 , M. Puoti 10 , M.G. Rumi 11 , A. Benedetti 12 , S. Fargion 13 , D. Ieluzzi 14 , G. Nardone 3 , F. Giuseppe 15 , A. Ciancio 16 , G. Taliani 17 , E. Biliotti 17 , S. Madonia 18 , B. Stagno 18 , A. Alberti 19 , M. Massari 20 , F. Rosina 21 , G. Mazzella 22 , A. Di Leo 23 , A. Iannone 23 , C. Ferrari 24 , A. Orlandini 24 , M. Monti 25 , T.A. Santantonio 26 , L. Chessa 27 , E.M. Erne 19 , C. Coppola 28 , M. Andreoni 29 , F. Baldelli 30 , M. Mondelli 31 , P. Blanc 32 , A. Gasbarrini 33 , G. Verucchi 34 , M. Colombo 35 , M. Borghi 36 , A. Craxì 37 , S. Petta 37 , E. Villa 38 , O. Patti 38 , F.P. Russo 19 , M. Strazzabosco 39 , S. Vella 1 , A.L. Zignego 25 . 1 Istituto Superiore di Sanità, Roma; 2 Ospedale Niguarda, Milano; 3 Università Federico II, Napoli; 4 AOU Pisana, Pisa; 5 Seconda Università degli Studi, Napoli; 6 Università di Padova, Padova; 7 Policlinico Sant’Orsola Malpighi, Bologna; 8 AOU Policlinico, Messina; 9 Ospedale G. da Procida, Salerno; 10 AO Niguarda-Cà Granda; 11 UO San Giuseppe, Milano; 12 Università Politecnica delle Marche, Ancona; 13 Fondazione IRCCS Ca’ Granda, Milano; 14 AOU Verona, Verona; 15 AO “Bianchi Malacrino-Morelli”, Reggio Calabria; 16 Ospedale Molinette, Torino; 17 Policlinico Umberto I, Roma; 18 Ospedale Cervello, Palermo; 19 AO Padova, Padova; 20 ASMN Reggio Emilia, Reggio Emilia; 21 Presidio Sanitario Gradenigo, Torino; 22 Ospedale Sant’Orsola Malpighi, Bologna; 23 AO Policlinico, Bari; 24 AOU Parma, Parma; 25 AOU Careggi, Firenze; 26 Ospedali Riuniti, Foggia; 27 AOU Cagliari, Cagliari; 28 Ospedale di Gragnano, Napoli; 29 Policlinico Universitario Tor Vergata, Roma; 30 Policlinico S. Maria della Misericordia, Perugia; 31 Policlinico San Matteo, Pavia; 32 Ospedale S.Maria Annunziata, Firenze; 33 Policlinico Gemelli, Roma; 34 Ospedale Sant’ Orsola Malpighi, Bologna; 35 Fondazione IRCCS Ospedale Maggiore Policlinico; 36 Fondazione IRCCS Ospedale Maggiore Policlinico, Milano; 37 Policlinico Giaccone, Palermo; 38 Università di Modena, Modena; 39 AO San Gerardo, Monza, Italy E-mail: lkondili@iss.it Background and Aims: HCV is the etiologic agent for the great majority of patients with mixed cryoglobulinemia (MC), however data regarding the large scale prevalence of this disorder are limited. The aim of this study was to evaluate the prevalence and the clinical profile of MC in patients enrolled in a real-life cohort of 7496 consecutive patients presenting for care at 80 Italian Units, collected over the last 12 months within the PITER framework. Methods: A specific questionnaire regarding the presence of crioglobulinemia and related symptoms was applied. MC was characterised at baseline according to the fibrosis stage and to the treatment history. Results: Of 7496 patients enrolled, the MC was never tested in 6019 (80%). The remaining 1477 HCV(+) patients were classified as follows: in 22% as symptomatic MC (MCS-HCV:mean age 64 + -11 years), in 29% as asymptomatic MC (MC-HCV: mean age 61 + -12 years), and in 49% as HCV infected patients without MC (mean age 60 + -13 years). Among the 328 patients declared to be “symptomatic”, detailed data that confirmed MCS were available for 252 (33% of patients with MC). MC symptoms included purpura, weakness, and arthralgia (MC triad), as well as peripheral neuropathy, sicca syndrome, myalgias, cutaneous ulcers and renal involvement. History of nocturnal sweet, fever and pruritis was also rarely reported. In patients with MCS the liver fibrosis stage, was F0-F1 in 40%; F2 in 12%; F3 in 13% and F4 in 35% of patients, with no significant differences among the different groups (p > 0.5). Previous IFN-based therapy was reported in 54% of MCS-HCV, in 45% of MC-HCV and in 50% of HCV patients.162 (65%) of MCS-HCV patients have been treated orare on treatment with DAA (in combination with immunosuppressants in 10% of cases). Only preliminary results of DAA’s treatment are available showing high rate of virological and clinical response with rare (1%: 3 patients) treatment interruption due to adverse events/intolerance. Conclusions: This nation-wide, in progress study showed that, in spite of the clinical and therapeutic importance of HCV-related MC (patients with clinically significant MC have been considered as prioritized group of treatment), the presence of this condition was not considered in the large majority of cases. Among patients with MC, a symptomatic form was observed in more than 30% of cases. Treated patients will be prospectively followed up to better characterize and define the long term outcome of such an important consequence of chronic HCV infection. FRI-182 THE IL10-819C/T IS ASSOCIATEDWITH MAJOR DEPRESSIVE DISORDER IN PATIENTS WITH CHRONIC HEPATITIS C L.R. Cunha 1 , D.A. Vieira 1 , Y.G. Giampietro 1 , A.D. Gomes 2 , C. Faria, Jr 2 , R. Teixeira 1,3 , O.A. Martins Filho 4 , F.S. Neves 5 , G.A. Rocha 2 , D.M. Queiroz 2 , L.D. Silva 3,6 . 1 Viral Hepatitis Ambulatory, Instituto Alfa de Gastroenterologia, Hospital das Clínicas, Universidade Federal de Minas Gerais; 2 Laboratory of Research in Bacteriology; 3 Internal Medicine, Faculdade De Medicina Da Universidade Federal De Minas Gerais; 4 Diagnoses and Monitoring Biomarkers Laboratory, Instituto René Rachou, Fundação Oswaldo Cruz; 5 Mental Health, Faculdade de Medicina da Universidade Federal de Minas Gerais; 6 Viral Hepatitis Ambulatory, Instituto Alfa de Gastroenterologia, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil E-mail: lucianadinizsilva@gmail.com POSTER PRESENTATIONS S619 Journal of Hepatology 2016 vol. 64 | S425–S630